MBX MBX Biosciences, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Clinical-stage biopharma developing novel precision peptide therapies for endocrine and metabolic disorders via proprietary PEP™ platform
• • New emphasis on once-weekly canvuparatide for chronic hypoparathyroidism with positive Phase 2 data; Phase 3 trial to start Q3 2026

Risk Factors

• • FDA regulatory risk: potential requirement for additional preclinical or clinical studies increasing costs and delaying approvals
• • Geopolitical/macroeconomic risk: $373.7M cash runway into 2029 threatened by economic uncertainty and geopolitical tensions impacting operations

Management Discussion & Analysis

• • Net loss $87.0M in 2025 vs $61.9M in 2024; operating expenses rose $29.9M to $98.1M
• • R&D expenses $79.2M (29.7% increase) driven by canvuparatide ($37.2M, up $15.6M) and MBX 4291 ($12.7M, up $1.9M); imapextide decreased $7.4M

What are the latest MBX SEC filings in 2026?

MBX Biosciences, Inc. (MBX) has filed a 10-K annual report on March 12, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on June 12, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did MBX file its most recent 10-K annual report?

MBX Biosciences, Inc. (MBX) filed its most recent 10-K annual report on March 12, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view MBX 10-Q quarterly reports?

MBX Biosciences, Inc. (MBX)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every MBX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has MBX filed recently?

MBX Biosciences, Inc. (MBX)'s most recent 8-K was filed on June 12, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find MBX insider trading activity (Form 4)?

SignalX aggregates every MBX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does MBX file with the SEC?

MBX Biosciences, Inc. (MBX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new MBX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for MBX Biosciences, Inc. (MBX).

What is MBX's SEC CIK number?

MBX Biosciences, Inc. (MBX)'s SEC CIK (Central Index Key) number is 1776111. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1776111 to look up all MBX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find MBX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from MBX Biosciences, Inc. (MBX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.